Global Pneumococcal Vaccine Market Growth 2023-2029

Global Pneumococcal Vaccine Market Growth 2023-2029

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
LPI (LP Information)' newest research report, the “Pneumococcal Vaccine Industry Forecast” looks at past sales and reviews total world Pneumococcal Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Pneumococcal Vaccine sales for 2023 through 2029. With Pneumococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pneumococcal Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pneumococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pneumococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pneumococcal Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pneumococcal Vaccine and breaks down the forecast by type, by end user, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pneumococcal Vaccine.
The global Pneumococcal Vaccine market size is projected to grow from US$ 7043.6 million in 2022 to US$ 7625.9 million in 2029; it is expected to grow at a CAGR of 7625.9 from 2023 to 2029.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
This report presents a comprehensive overview, market shares, and growth opportunities of Pneumococcal Vaccine market by product type, end user, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
PPSV 23
PCV 7/13
PCV 10
Segmentation by end user
Child
Adult
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Key Questions Addressed in this Report
What is the 10-year outlook for the global Pneumococcal Vaccine market?
What factors are driving Pneumococcal Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pneumococcal Vaccine market opportunities vary by end market size?
How does Pneumococcal Vaccine break out type, end user?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.